CJC-1295 Without DAC + Ipamorelin (10mg) Blend

Secra Labs CJC-1295 Without DAC + Ipamorelin Peptide Blend (10mg)

Secra Labs is proud to present a premium, pre-formulated peptide secretagogue blend designed for advanced laboratory applications. This synergistic combination utilizes two distinct signaling pathways to allow researchers to study potent and efficient growth hormone (GH) stimulation protocols.

Our CJC-1295 (Without DAC) + Ipamorelin blend is engineered to mimic natural physiological GH pulses, providing higher amplitude release profiles when studied in experimental models compared to secretagogues utilized in isolation.

Peptide Composition & Blend Specifics

This multi-dose vial contains a precisely balanced 10mg total lyophilized powder mixture, yielding exactly 5mg of each compound:

• CJC-1295 (Without DAC) — 5mg: A Growth Hormone Releasing Hormone (GHRH) analog.

• Ipamorelin — 5mg: A Ghrelin mimetic and Growth Hormone Releasing Peptide (GHRP).

This exact 1:1 formulation ensures maximum precision, allowing for highly reproducible dosing and consistent variables across your research applications.

The Synergistic Mechanism: Studies in Robust GH Output

Researchers investigate this combination for its multiplicative (rather than additive) effect on natural growth hormone release. This synergy is studied through two unique pathways:

1. Pulse Frequency (Ipamorelin): Acting as a GHRP, Ipamorelin increases the number of growth hormone pulses by inhibiting somatostatin. Ipamorelin is specifically studied for its high receptor selectivity, which has been shown to result in negligible effects on cortisol and prolactin secretion in previous models.

2. Pulse Amplitude (CJC-1295): The CJC-1295 (Without DAC) component increases the strength/amplitude of the pulse by stimulating the pituitary directly.

The unique combination allows laboratory observation of massive synergistic spikes in growth hormone secretion while maintaining natural physiological pulsation, avoiding the “GH bleed” often associated with continuous release secretagogues.

Research Applications & Study Focus

• Lipolysis & Metabolic Studies: Researching the influence of the blend on acute lipid mobilization and adipose tissue reduction mechanisms.

• Muscle Protein Synthesis: Investigation of synergistic signaling on lean tissue accretion and structural modeling.

• Wound Healing & Recovery Models: Studies evaluating the rate of connective tissue and dermal repair via insulin-like growth factor (IGF-1) pathways.

• Sleep and Neural Studies: Exploring the interactions between ghrelin mimetics and cognitive function/deep-wave sleep cycles in experimental subjects.

Product Quality & Specifications

Secra Labs utilizes rigorous stabilization protocols to ensure a minimum purity standard of 99.0% (as verified by independent HPLC and MS analysis) across both active peptide components. The product is provided non-pyrogenic.

• Format: White, lyophilized solid.

• Total Content: 10mg peptide secretagogue mixture (5mg CJC-1295 / 5mg Ipamorelin).

• Purity: Analytical Standard ≥99.0%.

• Vial Type: Glass multi-dose vial with purple flip-top cap.

• Purity Verification: The included QR code links directly to the Certificate of Analysis (CoA) for batch authenticity.

Handling and Storage Protocol

• Storage: Securely store lyophilized powder at -20°C for long-term preservation. Short-term storage at 2-8°C is acceptable prior to reconstitution.

• Reconstitution: Researchers must utilize strict aseptic technique when reconstituting the lyophilized powder and throughout all multi-dose usages.

---

IMPORTANT LEGAL DISCLAIMER: FOR RESEARCH ONLY

This product, CJC-1295 Without DAC + Ipamorelin, is supplied strictly for in-vitro laboratory research and development (R&D) purposes only. It has NOT been evaluated by the U.S. Food and Drug Administration (FDA) for human or veterinary safety or efficacy. It is explicitly not intended for, nor is it suitable for, human consumption, injection, diagnosis, treatment, cure, or prevention of any disease or condition. This peptide should only be handled by properly trained laboratory personnel. Under no circumstances should this peptide be administered outside of a controlled, non-clinical research protocol.